PPARG and colonic neoplasm: Previous studies showed that PPARγ can suppress beta-catenin levels and colon carcinogenesis but only before damage to the APC/beta-catenin pathway, suggesting a potentially important use for PPARγ ligands as chemopreventive agents in colon cancer [37, 38].